

# Estonia

Population 2016

1.3 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.016 (0.016–0.016)	1.2 (1.2–1.2)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.27 (0.18–0.38)
Incidence (includes HIV+TB)	0.22 (0.18–0.25)	16 (14–19)
Incidence (HIV+TB only)	0.023 (0.015–0.033)	1.8 (1.1–2.5)
Incidence (MDR/RR-TB)**	0.046 (0.031–0.06)	3.5 (2.3–4.6)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.01 (<0.01–0.012)	0.068 (0.058–0.078)	0.078 (0.066–0.09)
Males	0.011 (<0.01–0.012)	0.13 (0.11–0.15)	0.14 (0.12–0.16)
Total	0.021 (0.018–0.024)	0.2 (0.17–0.22)	0.22 (0.18–0.25)

TB case notifications, 2016	
Total cases notified	192
Total new and relapse	188
- % tested with rapid diagnostics at time of diagnosis	76%
- % with known HIV status	95%
- % pulmonary	93%
- % bacteriologically confirmed among pulmonary	86%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.09 (0.08–0.11)

TB/HIV care in new and relapse TB patients, 2016		
	Number	(%)
Patients with known HIV-status who are HIV-positive	21	12%
- on antiretroviral therapy	20	95%

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			34 (23–45)
Estimated % of TB cases with MDR/RR-TB	14% (8.3–21)	54% (25–81)	
% notified tested for rifampicin resistance	83%	84%	160
MDR/RR-TB cases tested for resistance to second-line drugs			26
Laboratory-confirmed cases		MDR/RR-TB: 26, XDR-TB: 7	
Patients started on treatment ****		MDR/RR-TB: 25, XDR-TB: 6	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2015	83%	172
Previously treated cases, excluding relapse, registered in 2015	100%	2
HIV-positive TB cases registered in 2015	81%	16
MDR/RR-TB cases started on second-line treatment in 2014	74%	42
XDR-TB cases started on second-line treatment in 2014	13%	8

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017	
National TB budget (US\$ millions)	1.2
Funding source: 100% domestic, 0% international, 0% unfunded	

\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically